Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | EYA2 | O00167 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223081 | 0.96 | TDP1 (0.65) | TDP1EYA2APPACETSHR | |
| SCHEMBL3926050 | 0.80 | TDP1 (0.65) | TDP1EYA2APPACETSHR | |
| SCHEMBL3930821 | 0.78 | TDP1 (0.62) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL3810357 | 0.76 | TDP1 (0.88) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL9128547 | 0.76 | TDP1 (0.88) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL15136 | 0.76 | TDP1 (1.00) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL1373 | 0.76 | TDP1 (1.00) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL16714076 | 0.76 | TDP1 (1.00) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL8607480 | 0.76 | TDP1 (1.00) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL3035039 | 0.76 | TDP1 (1.00) | TDP1EYA2APPACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822390-B2 | Scale inhibitor | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-09-02 | — | — | US | claimed |
| EP-2371923-B1 | Scale inhibitor | CLARIANT FINANCE BVI LTD (VG) | 2013-02-13 | — | — | EP | claimed |
| EP-2556130-A1 | SCALE INHIBITOR | Clariant Finance (BVI) Limited (VG) | 2013-02-13 | — | — | EP | claimed |
| US-20130023449-A1 | Scale Inhibitor | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-01-24 | — | — | US | claimed |
| EP-2155162-B1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | BAUSCH & LOMB (US) | 2012-11-21 | — | — | EP | claimed |
| WO-2011120655-A1 | SCALE INHIBITOR | CLARIANT INTERNATIONAL LTD (CH) | 2011-10-06 | — | — | WO | claimed |
| EP-2371923-A1 | Scale inhibitor | Clariant International Ltd. (CH) | 2011-10-05 | — | — | EP | claimed |
| EP-2155162-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | Bausch & Lomb Incorporated (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008137496-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | BAUSCH & LOMB INCORPORATED (US) | 2008-11-13 | — | — | WO | claimed |
| US-20080275000-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | SALIX PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | claimed |
| US-4285575-A | USING AN ELECTROCHROMIC ELECTROLYTE CONTAINING A CARBOXYLIC-CONTAINING COMPLEXING AGENT, A FERROUS SALT, A METAL SALT, AND A CHROMOGEN; DURABILITY | CANON KABUSHIKI KAISHA (JP) | 1981-08-25 | — | — | US | claimed |
| US-4212518-A | ELECTROCHROMIC CELL | CANON KABUSHIKI KAISHA (JP) | 1980-07-15 | — | — | US | claimed |
| EP-3434253-B1 | DENTAL ALGINATE IMPRESSION MATERIAL | G C DENTAL IND CORP (JP) | 2022-02-02 | — | — | EP | disclosed |
| US-10744071-B2 | Dental alginate impression material | GC CORPORATION (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20190076336-A1 | DENTAL ALGINATE IMPRESSION MATERIAL | GC CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3434253-A1 | ALGINATE IMPRESSION MATERIAL FOR DENTAL USE | GC Corporation (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-5346010-A | Precipitation of scale inhibitors in subterranean formations | SHELL OIL COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| US-4285575-A | USING AN ELECTROCHROMIC ELECTROLYTE CONTAINING A CARBOXYLIC-CONTAINING COMPLEXING AGENT, A FERROUS SALT, A METAL SALT, AND A CHROMOGEN; DURABILITY | CANON KABUSHIKI KAISHA (JP) | 1981-08-25 | — | — | US | disclosed |
| US-4212518-A | ELECTROCHROMIC CELL | CANON KABUSHIKI KAISHA (JP) | 1980-07-15 | — | — | US | disclosed |
| US-3935862-A | Inhibition of conditions arising from microbial production of ammonia | PERSONAL PRODUCTS COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275000-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | PDE6D, PDE6H, CA2 | TDP1 2430/4885EYA2 23/4885APP 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.